|
[1]Edward L, Krawitt MD.Autoimmune hepatitis[J].N Engl J Med, 2006, 354:54-66.
|
|
[2]Zachou K, Rigopoulou E, Dalekos GN.Autoanibodies and autoanti-gens in autoimmune hepatitis:important tools in clinical practice and to study pathogenesis of the disease[J].J Autoimmune Dis, 2004, 1:2.
|
|
[3]Dalekos GN, Zachou K, Liaskos C, et al.Autoantibodies and de-fined target autoantigens in autoimmune hepatitis:an overview[J].Eur JIntern Med, 2002, 13:293-303.
|
|
[4]Schreiter T, Liu C, Gerken G, et al.Detection of circulating au-toantibodies directed against the asialoglycoprotein receptor using re-combinant receptor subunit H1[J].J Immunol Methods, 2005, 301:1-10.
|
|
[5]Bridoux-Henno L, Maggiore G, Johanet C, et al.Features and out-come of autoimmune hepatitis type2presenting with isolated positivi-ty for anti-liver cytosolantibody[J].Clin Gastroenterol Hepatol, 2004, 2:825-830.
|
|
[6]Kato T, Miyakawa H, Ishibashi M.Frequency and significance of anti-glutathione S-transferase autoantibody (anti-GST A1-1) in autoimmune hepatitis[J].J Autoimmun, 2004, 22:211-216.
|
|
[7]Huguet S, Labas V, Duclos-Vallee JC, et al.Heterogeneous nucle-ar ribonucleoprotein A2/B1identified as an autoantigen in autoim-mune hepatitis by proteome analysis[J].Proteomics, 2004, 4:1341-1345.
|
|
[8]Wesiersk-Gadek J, Penner E, Buttezzati PM, et al.Correlation of initial autoantibody profile and elinical outcome in primary biliary cinhosis[J].Hepatology, 2006, 43 (5) :1135-1144.
|
|
[9]Benson GD, Kikuchi K, Miyakawa H, et al.Serial analysis of an-timitochondrial antibody in patients with primary biliary cirrhosis[J].Clin Dev Immunol, 2004, 36:129-133.
|
|
[10]Flisiak R, Pelszynska M, Prokopowicz D, et al.High concentration of antimitochondrial antibodies predicts progressive primary biliary cirrhosis[J].World J Gastroenterol, 2005, 36:5706-5709.
|
|
[11]Rigopoulou EI, Davies ET, Pares A.Prevalence and clinical signif-icance of is one type specific antinuclear antibodies in primary biliary cirrhosis[J].Gut, 2005, 54:528-532.
|
|
[12]von Landenberg P, Baumgartner M, Schoelmerich J, et al.Clinical relevance of antiphospholipid antibodies in primary biliary cirrhosis[J].Ann N Y Acad Sc, i2005, 1051:20-28.
|
|
[13]Bogdanos DP, Vergani D, Muratori P.Specificity of anti-sp100anti-body for primary biliary cirrhosis[J].Scand J Gastroenterol, 2004, 39:405-406.
|
|
[14]Rigopoulou EI, Dalekos GN.Anti-sp100antibodies in primary biliary cirrhosis[J].Scand J Gastroenterol, 2004, 39:406-407.
|
|
[15]Invernizzi P, Selmi C, Ranftler C, et al.Antinuclear antibodies in primary biliary cirrhosis[J].Semin Liver Dis, 2005, 25:298-310.
|
|
[16]Janka C, Selmi C, Gershwin ME.Small ubiquitin-related modifi-ers:a novel and independent class of autoantigens in primary biliary cirrhosis[J].Hepatology, 2005, 41:609-616.
|
|
[17]Nakamura M, Shimizu-Yoshida Y, Takii Y, et al.Antibody titer togp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis[J].J Hepatol, 2005, 42:386-392.
|
|
[18]Nakamura M, Takii Y, Ito M, et al.Increased expression of nucle-ar envelope gp210antigen in small bile ducts in primary biliary cir-rhosis[J].J Autoimmun, 2006, 26:138-145.
|
|
[19]Krawitt EL.Autoimmune hepatitis[J].N Engl J Med, 2006, 354:54-66.
|
PDF下载 ( 173 KB)
本文二维码
下载:
